Sally Barbour

2.0k total citations · 2 hit papers
21 papers, 1.1k citations indexed

About

Sally Barbour is a scholar working on Surgery, Pediatrics, Perinatology and Child Health and Geriatrics and Gerontology. According to data from OpenAlex, Sally Barbour has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 5 papers in Pediatrics, Perinatology and Child Health and 5 papers in Geriatrics and Gerontology. Recurrent topics in Sally Barbour's work include Nausea and vomiting management (7 papers), Pharmaceutical Practices and Patient Outcomes (5 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Sally Barbour is often cited by papers focused on Nausea and vomiting management (7 papers), Pharmaceutical Practices and Patient Outcomes (5 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Sally Barbour collaborates with scholars based in United States, Switzerland and Japan. Sally Barbour's co-authors include Mark G. Kris, Michael Danso, Kristopher Dennis, Karin Jordan, Cathy Eng, Dee Sparacio, Ethan Basch, Rebecca Clark-Snow, Kari Bohlke and Gary H. Lyman and has published in prestigious journals such as Journal of Clinical Oncology, CHEST Journal and Annals of Oncology.

In The Last Decade

Sally Barbour

21 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

2017 397 citations Paul J. Hesketh, Mark G. Kris et al. Journal of Clinical Oncology profile →
Antiemetics: ASCO Guideline Update

2020 224 citations Paul J. Hesketh, Mark G. Kris et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sally Barbour United States	10	620	307	211	206	198	21	1.1k
Nicholas Chiu United States	19	354 0.6×	175 0.6×	214 1.0×	66 0.3×	125 0.6×	54	971
Xavier Pourrat France	14	236 0.4×	54 0.2×	190 0.9×	147 0.7×	193 1.0×	35	906
Enzo Ballatori Italy	23	869 1.4×	375 1.2×	383 1.8×	70 0.3×	222 1.1×	78	1.6k
Leonard Chiu Canada	18	324 0.5×	179 0.6×	195 0.9×	31 0.2×	119 0.6×	42	780
Lori Holden Canada	23	671 1.1×	72 0.2×	599 2.8×	115 0.6×	413 2.1×	77	1.6k
James M. Watters Canada	16	379 0.6×	221 0.7×	139 0.7×	50 0.2×	180 0.9×	44	915
Kim Tran United States	13	307 0.5×	76 0.2×	119 0.6×	83 0.4×	107 0.5×	23	751
Patrick Bachmann France	21	255 0.4×	912 3.0×	473 2.2×	25 0.1×	201 1.0×	94	1.5k
Lin Xie United States	23	137 0.2×	47 0.2×	69 0.3×	99 0.5×	51 0.3×	88	1.4k
Monica Indelli Italy	13	136 0.2×	108 0.4×	798 3.8×	84 0.4×	188 0.9×	29	1.5k

Countries citing papers authored by Sally Barbour

Since Specialization

Citations

This map shows the geographic impact of Sally Barbour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sally Barbour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sally Barbour more than expected).

Fields of papers citing papers by Sally Barbour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sally Barbour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sally Barbour. The network helps show where Sally Barbour may publish in the future.

Co-authorship network of co-authors of Sally Barbour

This figure shows the co-authorship network connecting the top 25 collaborators of Sally Barbour. A scholar is included among the top collaborators of Sally Barbour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sally Barbour. Sally Barbour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Capozzi, Donna, et al.. (2023). Which hematology/oncology patients are high priority for ambulatory clinical pharmacist review? A three-round Delphi survey by the National Comprehensive Cancer Network. Journal of Oncology Pharmacy Practice. 29(8). 1907–1914. 1 indexed citations

Barbour, Sally, et al.. (2023). Value Assessment of Oncology Pharmacist Interventions. Journal of the Advanced Practitioner in Oncology. 14(4). 329–331. 1 indexed citations

Bush, Paul W., et al.. (2020). Evaluation of the Role and Impact of Ambulatory Clinical Pharmacists in an Academic Comprehensive Cancer Center. Journal of the Advanced Practitioner in Oncology. 11(8). 817–824. 9 indexed citations

Hesketh, Paul J., Mark G. Kris, Ethan Basch, et al.. (2020). Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology. 38(24). 2782–2797. 224 indexed citations breakdown →

Barbour, Sally, Teresa Smit, Daniel Powers, et al.. (2017). Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant. Annals of Oncology. 28(6). 1268–1273. 7 indexed citations

Hesketh, Paul J., Mark G. Kris, Ethan Basch, et al.. (2017). Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 35(28). 3240–3261. 397 indexed citations breakdown →

Moore, Russell, et al.. (2017). Incidence of skeletal related events in patients with bone metastasis receiving denosumab every four weeks compared to intervals greater than every four weeks. Journal of Oncology Pharmacy Practice. 25(3). 529–534. 2 indexed citations

Barbour, Sally. (2017). Management of Patients With Chemotherapy-Induced Nausea and Vomiting.. PubMed. 8(3). 303–308. 2 indexed citations

Ignoffo, Robert J., Katherine K. Knapp, Mitchell J. Barnett, et al.. (2016). Board-Certified Oncology Pharmacists: Their Potential Contribution to Reducing a Shortfall in Oncology Patient Visits. Journal of Oncology Practice. 12(4). e359–e368. 37 indexed citations

10.

Barbour, Sally, et al.. (2015). 1529 Low risk of drug interactions when rolapitant is coadministered with CYP2D6 or BCRP substrates: Integrated safety results. European Journal of Cancer. 51. S214–S214. 2 indexed citations

11.

Schwartzberg, Lee S., et al.. (2013). Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Supportive Care in Cancer. 22(2). 469–477. 63 indexed citations

12.

Barbour, Sally. (2012). Corticosteroids in the Treatment of Chemotherapy-Induced Nausea and Vomiting. Journal of the National Comprehensive Cancer Network. 10(4). 493–499. 19 indexed citations

13.

Wahidi, Momen M., Prasoon Jain, Michael A. Jantz, et al.. (2011). American College of Chest Physicians Consensus Statement on the Use of Topical Anesthesia, Analgesia, and Sedation During Flexible Bronchoscopy in Adult Patients. CHEST Journal. 140(5). 1342–1350. 180 indexed citations

14.

Barbour, Sally, et al.. (2011). Analysis of phase III clinical studies for palonosetron, ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).. Journal of Clinical Oncology. 29(15_suppl). 9091–9091. 1 indexed citations

15.

Abernethy, Amy P., Remy R Coeytaux, Douglas C McCrory, et al.. (2010). Report on the Evidence Regarding Off-Label Indications for Targeted Therapies used in Cancer Treatment. 2 indexed citations

16.

Valgus, John, et al.. (2010). Role of Oncology Clinical Pharmacists in Light of the Oncology Workforce Study. Journal of Oncology Practice. 6(5). 270–272. 50 indexed citations

17.

Ettinger, David S., Sally Barbour, Michael Berger, et al.. (2009). Antiemesis. Journal of the National Comprehensive Cancer Network. 7(5). 572–595. 83 indexed citations

18.

Abernethy, Amy P., Sally Barbour, Hope E. Uronis, et al.. (2008). Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. Supportive Care in Cancer. 17(6). 735–744. 6 indexed citations

19.

Barbour, Sally. (2008). Caring for the treatment-experienced breast cancer patient: The pharmacist’s role. American Journal of Health-System Pharmacy. 65(10_Supplement_3). S16–S22. 10 indexed citations

20.

Riedel, Richard F., Jennifer Garst, Frank Dunphy, et al.. (2007). A Phase II Trial of Carboplatin/Vinorelbine with Pegfilgrastim Support for the Treatment of Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(6). 520–525. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact